|
Sustained
Viral Response (SVR)
/ Rapid Virologic Response (RVR)
/ Early Viral Response (EVR)
/ End of Treatment Response (EOT)
Pre-treatment
with Ribavirin
Improves Response
to Interferon-based
Therapy for Hepatitis C
12/14/2010
Menopause
and Obesity Linked to HCV Relapse after Interferon-based
Treatment
12/10/2010
Drinking
More Coffee Linked to Improved
Response to Hepatitis C Treatment
12/03/2010
Sustained
Response to Hepatitis C Therapy Is Key to
Improved Survival after Liver Transplantation
11-05-2010
Week 4 Rapid
Virological Response Predicts Sustained
Response to Interferon-based Hepatitis C
Treatment
9-03-2010
Pegylated Interferon
plus Ribavirin Has High Sustained
Response Rates in Children with Hepatitis
C
8-31-2010
Response at Week
8 Accurately Predicts Sustained
Response to Pegylated Interferon plus Ribavirin
for Hepatitis C
7-05-2010
Sustained
Response to Antiviral Therapy Prevents Esophageal
Varices in Hepatitis C Patients with Cirrhosis
7-05-2010
Reappearance
of HCV in Gay Men Is Usually Due to Re-infection, Not
Late Relapse
7-05-2010
Blood-boosting
Adjuvant Therapies Can Improve Response
to Interferon-based Treatment for
Hepatitis C
6-25-2010
Sustained
Virological Response at 12 Weeks Post-treatment
May be as Good as 24 Weeks for Determining Interferon
Cure
6-11-2010
Vitamin
D Increases Sustained Response
to Interferon-based Therapy for Hepatitis C, May Improve
Liver Fibrosis
5-15-2010
HIV/HCV
Coinfected Patients with Acute Hepatitis C Are Equally
Likely to Achieve Sustained
Response with Interferon plus Ribavirin
5-07-2010
HCV
Therapeutic Vaccine GI-5005 Improves Rate of Sustained
Response to Interferon-based Therapy for
Hepatitis C
4-27-2010
Closely
Individualized Treatment with Pegylated Interferon plus
Ribavirin Is Possible Based on Baseline Viral Load and
Early Response
4-23-2010
Response
to Interferon-based Therapy Is Lower in HIV/HCV
Coinfected Patients than HCV Monoinfected, but Predicted
by Similar Factors
4-23-2010
Predictors of Rapid
and Early Virological Response to
Pegylated Interferon plus Ribavirin in Genotype
1 Hepatitis C Patients
4-9-2010
Older Hepatitis C
Patients Have More Side Effects from Interferon-based
Therapy, but Many Can Achieve Sustained
Response
3/30/2010
Sustained
Response to Interferon Reduces both Liver-related
and AIDS-related Disease and Death in HIV/HCV Coinfected
Patients
2-23-2010
Endothelial
Dysfunction Is Worse in People with HIV/HCV Coinfection,
but Improves with Sustained
Response to Hepatitis C Treatment
2-23-2010
Management of Non-responders
and Relapsers Treated with Pegylated Interferon plus
Ribavirin for Chronic Hepatitis C
1-5-2010
Low-dose Pegylated
Interferon Maintenance Therapy Does Not Reduce Clinical
Outcomes despite Persistent HCV
Suppression
1-5-2010
Patients with HBV/HCV
Coinfection May Experience HBV Relapse after Sustained
HCV Suppression
12/15/09
Chronic
Hepatitis C Patients over Age 50 Are Less Likely to
Achieve Sustained Treatment
Response
12/04/09
Sustained
Response to Interferon-based Therapy Leads
to Improved Quality of Life in Chronic Hepatitis C Patients
12/11/09
Hepatitis C Patients
over Age 50 Are Less Likely to Achieve Sustained
Treatment Response
12/01/09
Sustained
Virological Response to Interferon-based
Therapy Slows Progression of Liver Cirrhosis in Hepatitis
C Patients
11/24/09
Genotype
1 Chronic Hepatitis C Patients with Low Viral Load Can
Achieve Sustained Response
with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09
Individually
Tailored Duration of Hepatitis C Treatment Does Not
Improve Virological Response
10/30/09
Interferon-based Therapy
for Hepatitis C Improves Fibrosis Even in Individuals
without Virological Response
4/21/09
Sustained
Response to Interferon-based Therapy Reduces
Risk of Diabetes in Hepatitis C Patients
4/21/09
A
Small Proportion of Hepatitis C Patients Develop Liver
Cancer despite Sustained Response
to Interferon-based Therapy
4/13/09
Hepatitis
C Virus May Persists at Low Levels after Sustained
Response to Treatment; Liver Cancer May Develop
Years Later
2/06/2009
Extended
Pegylated Interferon plus Ribavirin Therapy Improves
Sustained Response Rate in
Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009
Adherence
to Pegylated Interferon/ribavirin Therapy for Hepatitis
C and Early Treatment Response
1/30/2009
Sustained Virological Response Indicates
Long-term HCV Eradication in People Successfully Treated
for Chronic Hepatitis C
10/14/08
Higher
Doses of Pegylated Interferon and Ribavirin May Increase
Sustained Response Rates
in Hard-to-Treat Patients with Chronic Hepatitis C
10/10/08
Sustained
Virological Response
to Pegylated Interferon plus Ribavirin for Chronic Hepatitis
C Does Not Always Prevent Hepatocellular Carcinoma
10/10/08
Genetic
Variation Linked to Sustained
Response to Pegylated Interferon plus Ribavirin
in HALT-C Trial
9/09/2008
Rapid Viral Response and Sustained
Treatment Outcome: A Comparison between 2
HCV RNA Assays
8/05/2008
Eight
Weeks of Pegylated Interferon plus Ribavirin for Genotype
2 Chronic HCV Patients with Rapid
Virological Response (RVR)
8/05/2008
74
Percent of Genotype 1 HCV Patients in Experimental HCV
PI Boceprevir Phase II Study Achieve Sustained
Virologic Response (SVR) at 48 Weeks
8/05/2008
Telaprevir
plus Pegylated Interferon and Ribavirin Produces Rapid
Response and Is Well Tolerated in 28-day
Study
7/22/08
Adequate
Ribavirin Exposure after the First Dose Predicts Sustained
Virological Response to Hepatitis C Treatment
in Genotype 1 Patients
7/08/08
HCV
Genotype 1 Patients with High Viral Load Do Better with
48 vs 24 Weeks of Treatment, despite Rapid
Virological Response
7/04/08
European
Commission Approves Shorter 16-week Course of Pegasys
plus Ribavirin for Rapid Responders
with HCV Genotypes 2 or 3 and Low Viral Load
7/04/08
Sustained
Response to Interferon-based Therapy
Reduces the Likelihood of Type 2 Diabetes
-
6/24/08
|
